NASDAQ:SLDB
Solid Biosciences Inc. Stock News
$10.39
+0.0500 (+0.484%)
At Close: May 10, 2024
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results
04:11pm, Monday, 16'th Aug 2021
- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 -
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
08:00am, Friday, 02'nd Jul 2021
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
07:35am, Monday, 07'th Jun 2021
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
07:30am, Monday, 07'th Jun 2021
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Solid Biosciences to Present at Upcoming Scientific Conferences
04:03pm, Tuesday, 25'th May 2021
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q1 2021 Results - Earnings Call Transcript
02:52pm, Friday, 14'th May 2021
Solid Biosciences' (SLDB) CEO Ilan Ganot on Q1 2021 Results - Earnings Call Transcript
Solid Biosciences (SLDB) Stock: Over 20% Decrease Explanation
02:05pm, Friday, 14'th May 2021
The stock price of Solid Biosciences Inc (NASDAQ: SLDB) decreased by over 20% during intraday trading. This is why it happened.
Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results
07:30am, Friday, 14'th May 2021
- Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event -
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
07:30am, Tuesday, 20'th Apr 2021
CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne)
Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
07:30am, Thursday, 25'th Mar 2021
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne)
Should You Buy Solid Biosciences (SLDB) Ahead of Earnings?
09:57am, Wednesday, 24'th Mar 2021
Solid Biosciences (SLDB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Edgewise Therapeutics Proposes Terms For $150 Million IPO
05:48pm, Tuesday, 23'rd Mar 2021
Edgewise Therapeutics has filed to raise $150 million in an IPO.
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
04:22pm, Tuesday, 23'rd Mar 2021
CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne
Solid Biosciences Announces Pricing of Public Offering of Common Stock
09:14pm, Thursday, 18'th Mar 2021
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne)
Solid Biosciences Announces Proposed Public Offering of Common Stock
04:20pm, Wednesday, 17'th Mar 2021
CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne
